Dr. Parth Rali Provides Perspective to Medscape on Results Presented at ERS on Mosliciguat, Potential Medication for Pulmonary Hypertension in Interstitial Lung Disease

Parth M. Rali, MD, FCCP, Director of the Temple University Health System Pulmonary Embolism Response Team (PERT) Program, provided perspective for a Medscape article on results presented at the European Respiratory Society (ERS) Congress on mosliciguat. Mosliciguat, a potential first-in-class inhaled medication, demonstrated significantly reduced pulmonary vascular resistance in adults with pulmonary hypertension associated with interstitial lung disease (PH-ILD) in the phase 2 PHocus study.